



WIKIPEDIA
The Free Encyclopedia

[Main page](#)

[Contents](#)

[Featured content](#)

[Current events](#)

[Random article](#)

[Donate to Wikipedia](#)

[Wikipedia store](#)

Interaction

[Help](#)

[About Wikipedia](#)

[Community portal](#)

[Recent changes](#)

[Contact page](#)

Tools

[What links here](#)

[Related changes](#)

[Upload file](#)

[Special pages](#)

[Permanent link](#)

[Page information](#)

[Cite this page](#)


Print/export

[Create a book](#)

[Download as PDF](#)

[Printable version](#)

Languages



Article [Talk](#)

[Read](#)

[Edit](#)

[View history](#)



Heart failure

From Wikipedia, the free encyclopedia

(Redirected from [ESC algorithm](#))

Heart failure (**HF**), often referred to as **chronic heart failure** (**CHF**), occurs when the [heart](#) is unable to pump sufficiently to maintain [blood flow](#) to meet the body's needs.^{[1][2][3]} The terms **congestive heart failure** (**CHF**) or **congestive cardiac failure** (**CCF**) are often used interchangeably with chronic heart failure.^[4] Signs and symptoms commonly include [shortness of breath](#), [excessive tiredness](#), and [leg swelling](#).^[5] The shortness of breath is usually worse with [exercise](#), while [lying down](#), and [may wake the person at night](#).^[5] A limited ability to exercise is also a common feature.^[6]

Common causes of heart failure include [coronary artery disease](#) including a previous [myocardial infarction](#) (heart attack), [high blood pressure](#), [atrial fibrillation](#), [valvular heart disease](#), [excess alcohol use](#), [infection](#), and [cardiomyopathy](#) of an unknown cause.^{[5][7]} These cause heart failure by changing either the structure or the functioning of the heart.^[5] There are two main types of heart failure: *heart failure due to left ventricular dysfunction* and *heart failure with normal [ejection fraction](#)* depending on if the ability of the [left ventricle](#) to contract is affected, or the heart's ability to relax.^[5] The severity of disease is usually graded by the degree of problems with exercise.^[8] Heart failure is not the same as myocardial infarction (in which part of the heart muscle dies) or [cardiac arrest](#) (in which blood flow stops altogether).^{[9][10]} Other diseases that may have symptoms similar to heart failure include [obesity](#), [kidney failure](#), liver problems, [anemia](#) and [thyroid disease](#).^[8]

The condition is diagnosed based on the history of the symptoms and a physical examination with confirmation by [echocardiography](#).^[11] [Blood tests](#), [electrocardiography](#), and [chest radiography](#) may be useful to determine the underlying cause.^[11] Treatment depends on the severity and cause of the disease.^[11] In people with chronic stable mild heart failure, treatment commonly consists of lifestyle modifications such as [stopping smoking](#),^[12] [physical exercise](#),^[13] and dietary changes, as well as medications.^[12] In those with heart failure due to left ventricular dysfunction, [angiotensin converting enzyme inhibitors](#) or [angiotensin receptor blockers](#) along with [beta blockers](#) are recommended.^[11] For those with severe disease, [aldosterone antagonists](#), or [hydralazine](#) plus a [nitrate](#) may be used.^[11] [Diuretics](#) are useful for preventing fluid retention.^[12] Sometimes, depending on the cause, an implanted device such as a [pacemaker](#) or an [implantable cardiac defibrillator](#) may be recommended.^[11] In some moderate or severe cases [cardiac resynchronization therapy](#) (CRT) may be suggested^[14] or [cardiac contractility modulation](#) may be of benefit.^[15] A [ventricular assist device](#) or occasionally a [heart transplant](#) may be recommended in those with severe disease despite all other measures.^[12]

Heart failure is a common, costly, and potentially fatal condition.^[7] In developed countries, around 2% of adults have heart failure and in those over the age of 65, this increases to 6–10%.^{[7][16]} In the year after diagnosis the risk of death is about 35% after which it decreases to below 10% each year.^[5] This is similar to the risks with a number of types of cancer.^[5] In the United Kingdom the disease is the reason for 5% of emergency hospital admissions.^[5] Heart failure has been known since ancient times with the [Ebers papyrus](#) commenting on it around 1550 BCE.^[6]

Contents [\[hide\]](#)


[1 Terminology](#)

[2 Signs and symptoms](#)

[2.1 Left-sided failure](#)

[2.2 Right-sided failure](#)

Heart failure



The major signs and symptoms of heart failure

Classification and external resources

Specialty	Cardiology
ICD-10	I50 ↗
ICD-9-CM	428.0 ↗
DiseasesDB	16209 ↗
MedlinePlus	000158 ↗
Patient UK	Heart failure ↗
MeSH	D006333 ↗

2.3 Biventricular failure
3 Causes
3.1 Congestive heart failure
3.2 Acute decompensation
4 Pathophysiology
4.1 Systolic dysfunction
4.2 Diastolic dysfunction
5 Diagnosis
5.1 Imaging
5.2 Electrophysiology
5.3 Blood tests
5.4 Angiography
5.5 Monitoring
5.6 Classification
5.7 Algorithms
5.8 Differential diagnosis
6 Management
6.1 Acute decompensation
6.2 Chronic management
6.3 Palliative care
7 Prognosis
8 Epidemiology
8.1 Sex
9 Economics
10 Research
11 References
12 External links

Terminology [\[edit\]](#)

Heart failure is a physiological state in which **cardiac output** is insufficient to meet the needs of the body and lungs. The term "congestive heart failure" is often used as one of the common symptoms is **swelling** or water retention.^[17]

Heart failure is divided into two different types: heart failure due to reduced ejection fraction (also known as heart failure due to left ventricular systolic dysfunction or systolic heart failure) and heart failure with preserved ejection fraction (HFpEF) also known as **diastolic heart failure** or heart failure with normal ejection fraction.^{[5][13]} Heart failure with reduced ejection fraction occurs when the ejection fraction is less than 40%.^[18] In diastolic heart failure, the heart muscle contracts well but the ventricle does not fill with blood well in the relaxation phase.^[5] **Ejection fraction** is the proportion of blood pumped out of the heart during a single contraction.^[19] It is given as a percentage with the normal range being between 50 and 75%.^[19]

The term "acute" is used to mean rapid onset, and "chronic" refers to long duration. Chronic heart failure is a long term condition, usually kept stable by the treatment of symptoms. **Acute decompensated heart failure** is a worsening of chronic heart failure symptoms which can result in **acute respiratory distress**.^[20] **High-output heart failure** can occur when there is an increased cardiac output. The circulatory overload caused, can result in an increased left ventricular diastolic pressure which can develop into pulmonary edema.^[21]

Signs and symptoms [\[edit\]](#)

Heart failure symptoms are traditionally and somewhat arbitrarily divided into "left" and "right" sided, recognizing that the left and right ventricles of the heart supply different portions of the circulation. However, heart failure is not exclusively *backward failure* (in the part of the circulation which drains to the ventricle).

There are several other exceptions to a simple left-right division of heart failure symptoms. Additionally, the most common cause of right-sided heart failure is left-sided heart failure.^[22] The result is that patients commonly present with both sets of signs and symptoms.

Left-sided failure [\[edit\]](#)

The left side of the heart is responsible for receiving oxygen-rich blood from the lungs and pumping it forward to the rest of the body. Failure of the left side of the heart causes blood to back up (be congested) into the lungs, causing respiratory symptoms as well as fatigue due to insufficient supply of oxygenated blood. Common respiratory signs are **increased rate of breathing** and increased *work* of breathing (non-specific signs of

respiratory distress). **Rales** or crackles, heard initially in the lung bases, and when severe, throughout the lung fields suggest the development of **pulmonary edema** (fluid in the **alveoli**). **Cyanosis** which suggests severe **low blood oxygen**, is a late sign of extremely severe pulmonary edema.

Additional signs indicating left ventricular failure include a laterally displaced **apex beat** (which occurs if the heart is enlarged) and a **gallop rhythm** (additional heart sounds) may be heard as a marker of increased blood flow, or increased intra-cardiac pressure. **Heart murmurs** may indicate the presence of valvular heart disease, either as a cause (e.g. **aortic stenosis**) or as a result (e.g. **mitral regurgitation**) of the heart failure.

Backward failure of the left ventricle causes congestion of the lungs' blood vessels, and so the symptoms are predominantly respiratory in nature. Backward failure can be subdivided into failure of the left atrium, the left ventricle or both within the left circuit. The patient will have **dyspnea** (shortness of breath) on exertion and in severe cases, dyspnea at rest. Increasing breathlessness on lying flat, called **orthopnea**, occurs. It is often measured in the number of pillows required to lie comfortably, and in **orthopnea**, the patient may resort to sleeping while sitting up. Another symptom of heart failure is **paroxysmal nocturnal dyspnea**: a sudden nighttime attack of severe breathlessness, usually several hours after going to sleep. Easy **fatigability** and exercise intolerance are also common complaints related to respiratory compromise.

"**Cardiac asthma**" or **wheezing** may occur.

Compromise of left ventricular **forward** function may result in symptoms of poor systemic circulation such as **dizziness**, **confusion** and cool extremities at rest.

Right-sided failure [\[edit\]](#)

Physical examination may reveal pitting peripheral **edema**, **ascites**, and **liver enlargement**. **Jugular venous pressure** is frequently assessed as a marker of fluid status, which can be accentuated by eliciting **hepatojugular reflux**. If the right ventricular pressure is increased, a **parasternal heave** may be present, signifying the compensatory increase in contraction strength.

Backward failure of the right ventricle leads to congestion of systemic capillaries. This generates excess fluid accumulation in the body. This causes swelling under the skin (termed **peripheral edema** or **anasarca**) and usually affects the dependent parts of the body first (causing foot and ankle swelling in people who are standing up, and **sacral** edema in people who are predominantly lying down). **Nocturia** (frequent nighttime urination) may occur when fluid from the legs is returned to the bloodstream while lying down at night. In progressively severe cases, **ascites** (fluid accumulation in the abdominal cavity causing swelling) and liver enlargement may develop. Significant liver congestion may result in **impaired liver function**, and jaundice and even **coagulopathy** (problems of decreased blood clotting) may occur.

Biventricular failure [\[edit\]](#)

Dullness of the lung fields to finger percussion and reduced breath sounds at the bases of the lung may suggest the development of a **pleural effusion** (fluid collection in between the lung and the chest wall). Though it can occur in isolated left- or right-sided heart failure, it is more common in biventricular failure because pleural veins drain into both the systemic and pulmonary venous systems. When unilateral, effusions are often right



Aman with congestive heart failure and marked **jugular venous distension**. External jugular vein marked by an arrow.



Severe peripheral edema

sided.

Causes [\[edit\]](#)

Congestive heart failure [\[edit\]](#)

Heart failure may also occur in situations of "high output," (termed "**high output cardiac failure**") where the ventricular systolic function is normal but the heart cannot deal with an important augmentation of blood volume.^[21] This can occur in overload situation (blood or serum infusions), kidney diseases, chronic severe **anemia**, **beriberi** (vitamin B₁/**thiamine** deficiency), **thyrotoxicosis**, **Paget's disease**, **arteriovenous fistulae**, or **arteriovenous malformations**.

Viral infections of the heart can lead to **inflammation of the muscular layer of the heart** and subsequently contribute to the development of heart failure. **Heart damage** can predispose a person to develop heart failure later in life and has many causes including systemic viral infections (e.g., **HIV**), **chemotherapeutic agents** such as **daunorubicin** and **trastuzumab**, and **abuse** of drugs such as **alcohol** and **methamphetamine**. Additionally, infiltrative disorders such as **amyloidosis** and **connective tissue diseases** such as **systemic lupus erythematosus** have similar consequences. **Obstructive sleep apnea** (a condition of sleep wherein disordered breathing overlaps with obesity, hypertension, and/or diabetes) is regarded as an independent cause of heart failure.

Acute decompensation [\[edit\]](#)

*Main article: **Acute decompensated heart failure***

Chronic stable heart failure may easily **decompensate**. This most commonly results from an intercurrent illness (such as **pneumonia**), **myocardial infarction** (a heart attack), **abnormal heart rhythms**, uncontrolled **hypertension**, or a patient's failure to maintain a fluid restriction, diet, or medication.^[23] Other well recognized factors that may worsen CHF include the following: **anemia** and **hyperthyroidism** which place additional strain on the heart muscle, excessive fluid or salt intake, and medication that causes fluid retention such as **NSAIDs** and **thiazolidinediones**.^[24] NSAIDs in general increase the risk twofold.^[25]

Pathophysiology [\[edit\]](#)

Heart failure is caused by any condition which reduces the efficiency of the heart muscle, through damage or overloading. As such, it can be caused by a wide number of conditions, including myocardial infarction (in which the heart muscle is **starved of oxygen** and dies), hypertension (which increases the force of contraction needed to pump blood) and **amyloidosis** (in which misfolded proteins are deposited in the heart muscle, causing it to stiffen). Over time these increases in workload will produce changes to the heart itself:

The heart of a person with heart failure may have a reduced force of contraction due to overloading of the **ventricle**. In a healthy heart, increased filling of the ventricle results in increased contraction force (by the **Frank–Starling law of the heart**) and thus a rise in **cardiac output**. In heart failure this mechanism fails, as the ventricle is loaded with blood to the point where heart muscle contraction becomes less efficient. This is due to reduced ability to cross-link **actin** and **myosin** filaments in over-stretched heart muscle.^[26]

A reduced **stroke volume** may occur as a result of a failure of **systole**, **diastole** or both. Increased **end systolic volume** is usually caused by reduced contractility. Decreased **end diastolic volume** results from impaired ventricular filling; this occurs when the compliance of the ventricle falls (i.e. when the walls stiffen). As the heart works harder to meet normal metabolic demands, the amount cardiac output can increase in times of increased oxygen demand (e.g., exercise) is reduced. This contributes to the exercise intolerance commonly seen in heart failure. This translates to the loss of one's **cardiac reserve**, or the ability of the heart to work harder during strenuous physical activity. Since the heart has to work harder to meet the normal metabolic demands, it is incapable of meeting the metabolic demands of the body during exercise.

A common finding in those with heart failure is an increased heart rate, stimulated by increased **sympathetic activity**^[27] in order to maintain an adequate cardiac output. Initially, this helps compensate for heart failure by maintaining blood pressure and perfusion, but places further strain on the myocardium, increasing coronary perfusion requirements, which can lead to worsening of ischemic heart disease. Sympathetic activity may also cause potentially fatal **abnormal heart rhythms**. **An increase in the physical size** of the heart's muscular layer may occur. This is caused by the terminally differentiated heart muscle fibers increasing in size in an attempt to improve contractility. This may contribute to the increased stiffness and decreased ability to relax during diastole. Enlargement of the ventricles can also occur and contributes to the enlargement and spherical shape of the failing heart. The increase in ventricular volume also causes a reduction in stroke volume due to mechanical and inefficient contraction of the heart.^[28]

The general effect is one of reduced cardiac output and increased strain on the heart. This increases the risk

of cardiac arrest (specifically due to abnormal ventricular heart rhythms), and reduces blood supply to the rest of the body. In chronic disease the reduced cardiac output causes a number of changes in the rest of the body, some of which are physiological compensations, some of which are part of the disease process:

- Arterial blood pressure falls. This destimulates [baroreceptors](#) in the [carotid sinus](#) and [aortic arch](#) which link to the [nucleus tractus solitarius](#). This center in the brain increases sympathetic activity, releasing catecholamines into the blood stream. Binding to alpha-1 receptors results in systemic arterial [vasoconstriction](#). This helps restore blood pressure but also increases the total peripheral resistance, increasing the workload of the heart. Binding to beta-1 receptors in the myocardium increases the heart rate and makes contractions more forceful in an attempt to increase cardiac output. This also, however, increases the amount of work the heart has to perform.
- Increased sympathetic stimulation also causes the posterior pituitary to secrete [vasopressin](#) (also known as antidiuretic hormone or ADH), which causes fluid retention at the kidneys. This increases the blood volume and blood pressure.
- Reduced [perfusion](#) (blood flow) to the kidneys stimulates the release of [renin](#) – an enzyme which catalyses the production of the potent vasopressor [angiotensin](#). Angiotensin and its metabolites cause further vasoconstriction, and stimulate increased secretion of the steroid [aldosterone](#) from the [adrenal glands](#). This promotes salt and fluid retention at the kidneys.
- The chronically high levels of circulating neuroendocrine hormones such as [catecholamines](#), renin, angiotensin, and aldosterone affects the myocardium directly, causing structural remodelling of the heart over the long term. Many of these remodelling effects seem to be mediated by transforming growth factor beta (TGF-beta), which is a common downstream target of the signal transduction cascade initiated by catecholamines^[29] and angiotensin II,^[30] and also by epidermal growth factor (EGF), which is a target of the signaling pathway activated by aldosterone^[31]
- Reduced perfusion of skeletal muscle causes atrophy of the muscle fibers. This can result in weakness, increased fatigueability and decreased peak strength – all contributing to exercise intolerance.^[32]

The increased peripheral resistance and greater blood volume place further strain on the heart and accelerates the process of damage to the myocardium. Vasoconstriction and fluid retention produce an increased hydrostatic pressure in the capillaries. This shifts the balance of forces in favour of [interstitial fluid](#) formation as the increased pressure forces additional fluid out of the blood, into the tissue. This results in [edema](#) (fluid build-up) in the tissues. In right-sided heart failure this commonly starts in the ankles where venous pressure is high due to the effects of gravity (although if the patient is bed-ridden, fluid accumulation may begin in the sacral region.) It may also occur in the abdominal cavity, where the fluid build-up is called ascites. In left-sided heart failure [edema](#) can occur in the lungs – this is called cardiogenic [pulmonary edema](#). This reduces spare capacity for ventilation, causes stiffening of the lungs and reduces the efficiency of gas exchange by increasing the distance between the air and the blood. The consequences of this are [dyspnea](#) (shortness of breath), [orthopnea](#) and [paroxysmal nocturnal dyspnea](#).

The symptoms of heart failure are largely determined by which side of the heart fails. The left side pumps blood into the systemic circulation, whilst the right side pumps blood into the [pulmonary circulation](#). Whilst left-sided heart failure will reduce cardiac output to the systemic circulation, the initial symptoms often manifest due to effects on the pulmonary circulation. In systolic dysfunction, the ejection fraction is decreased, leaving an abnormally elevated volume of blood in the left ventricle. In diastolic dysfunction, end-diastolic ventricular pressure will be high. This increase in volume or pressure backs up to the left atrium and then to the pulmonary veins. Increased volume or pressure in the pulmonary veins impairs the normal drainage of the alveoli and favors the flow of fluid from the capillaries to the lung parenchyma, causing pulmonary edema. This impairs gas exchange. Thus, left-sided heart failure often presents with respiratory symptoms: shortness of breath, orthopnea and paroxysmal nocturnal dyspnea.

In severe cardiomyopathy, the effects of decreased cardiac output and poor perfusion become more apparent, and patients will manifest with cold and clammy extremities, cyanosis, claudication, generalized weakness, dizziness, and [fainting](#).

The resultant [low blood oxygen](#) caused by pulmonary edema causes vasoconstriction in the pulmonary circulation, which results in pulmonary hypertension. Since the right ventricle generates far lower pressures than the left ventricle (approximately 20 mmHg versus around 120 mmHg, respectively, in the healthy individual) but nonetheless generates cardiac output exactly equal to the left ventricle, this means that a small increase in pulmonary vascular resistance causes a large increase in amount of work the right ventricle must perform. However, the main mechanism by which left-sided heart failure causes right-sided heart failure is actually not well understood. Some theories invoke mechanisms that are mediated by neurohormonal activation.^[33] Mechanical effects may also contribute. As the left ventricle distends, the intraventricular septum bows into the

right ventricle, decreasing the capacity of the right ventricle.

Systolic dysfunction [\[edit\]](#)

Heart failure caused by systolic dysfunction is more readily recognized. It can be simplistically described as failure of the pump function of the heart. It is characterized by a decreased ejection fraction (less than 45%). The strength of ventricular contraction is attenuated and inadequate for creating an adequate stroke volume, resulting in inadequate cardiac output. In general, this is caused by dysfunction or destruction of cardiac myocytes or their molecular components. In congenital diseases such as [Duchenne muscular dystrophy](#), the molecular structure of individual myocytes is affected. Myocytes and their components can be damaged by inflammation (such as in [myocarditis](#)) or by infiltration (such as in amyloidosis). Toxins and pharmacological agents (such as [ethanol](#), [cocaine](#), [doxorubicin](#), and [amphetamines](#)) cause intracellular damage and oxidative stress. The most common mechanism of damage is ischemia causing infarction and [scar formation](#). After myocardial infarction, dead myocytes are replaced by scar tissue, deleteriously affecting the function of the myocardium. On echocardiogram, this is manifest by abnormal wall motion (hypokinesia) or absent wall motion (akinesia).

Because the ventricle is inadequately emptied, ventricular end-diastolic pressure and volumes increase. This is transmitted to the atrium. On the left side of the heart, the increased pressure is transmitted to the pulmonary vasculature, and the resultant hydrostatic pressure favors extravasation of fluid into the lung parenchyma, causing pulmonary edema. On the right side of the heart, the increased pressure is transmitted to the systemic venous circulation and systemic capillary beds, favoring extravasation of fluid into the tissues of target organs and extremities, resulting in dependent [peripheral edema](#).

Diastolic dysfunction [\[edit\]](#)

Heart failure caused by diastolic dysfunction is generally described as the failure of the ventricle to adequately relax and typically denotes a stiffer ventricular wall. This causes inadequate filling of the ventricle, and therefore results in an inadequate stroke volume. The failure of ventricular relaxation also results in elevated end-diastolic pressures, and the end result is identical to the case of systolic dysfunction (pulmonary edema in left heart failure, peripheral edema in right heart failure).

Diastolic dysfunction can be caused by processes similar to those that cause systolic dysfunction, particularly causes that affect cardiac remodeling.

Diastolic dysfunction may not manifest itself except in physiologic extremes if systolic function is preserved. The patient may be completely asymptomatic at rest. However, they are exquisitely sensitive to increases in heart rate, and sudden bouts of tachycardia (which can be caused simply by physiological responses to exertion, fever, or dehydration, or by pathological tachyarrhythmias such as [atrial fibrillation with rapid ventricular response](#)) may result in [flash pulmonary edema](#). Adequate rate control (usually with a pharmacological agent that slows down AV conduction such as a calcium channel blocker or a beta-blocker) is therefore key to preventing decompensation.


Left ventricular diastolic function can be determined through echocardiography by measurement of various parameters such as the [E/A ratio](#) (early-to-atrial left ventricular filling ratio), the E (early left ventricular filling) deceleration time, and the [isovolumic relaxation time](#).

Diagnosis [\[edit\]](#)

No system of diagnostic criteria has been agreed on as the [gold standard](#) for heart failure. The [National Institute for Health and Care Excellence](#) recommends measuring [brain natriuretic peptide](#) followed by [ultrasound of the heart](#) if positive.^[34]

Imaging [\[edit\]](#)

[Echocardiography](#) is commonly used to support a clinical diagnosis of heart failure. This modality uses [ultrasound](#) to determine the [stroke volume](#) (SV, the amount of blood in the heart that exits the ventricles with each beat), the [end-diastolic volume](#) (EDV, the total amount of blood at the end of diastole), and the SV in proportion to the EDV, a value known as the [ejection fraction](#) (EF). In pediatrics, the [shortening fraction](#) is the preferred measure of



Acute pulmonary edema. Note enlarged heart size, apical vascular redistribution (circle), and small bilateral pleural effusions (arrow).

systolic function. Normally, the EF should be between 50% and 70%; in systolic heart failure, it drops below 40%. Echocardiography can also identify valvular heart disease and assess the state of the [pericardium](#) (the connective tissue sac surrounding the heart). Echocardiography may also aid in deciding what treatments will help the patient, such as medication, insertion of an [implantable cardioverter-defibrillator](#) or [cardiac resynchronization therapy](#). Echocardiography can also help determine if acute myocardial ischemia is the precipitating cause, and may manifest as regional wall motion abnormalities on echo.

[Chest X-rays](#) are frequently used to aid in the diagnosis of CHF. In a person who is compensated, this may show [cardiomegaly](#) (visible enlargement of the heart), quantified as the *cardiothoracic ratio* (proportion of the heart size to the chest). In left ventricular failure, there may be evidence of vascular redistribution ("upper lobe blood diversion" or "cephalization"), [Kerley lines](#), [cuffing of the areas around the bronchi](#), and interstitial edema. Ultrasound of the lung may also be able to detect Kerley lines.^[35]

Electrophysiology [\[edit\]](#)

An [electrocardiogram](#) (ECG/EKG) may be used to identify arrhythmias, [ischemic heart disease](#), [right](#) and [left ventricular hypertrophy](#), and presence of conduction delay or abnormalities (e.g. [left bundle branch block](#)). Although these findings are not specific to the diagnosis of heart failure a normal ECG virtually excludes left ventricular systolic dysfunction.^[36]

Blood tests [\[edit\]](#)

[Blood tests](#) routinely performed include [electrolytes](#) ([sodium](#), [potassium](#)), measures of [renal function](#), [liver function tests](#), [thyroid function tests](#), a [complete blood count](#), and often [C-reactive protein](#) if infection is suspected. An elevated [B-type natriuretic peptide](#) (BNP) is a specific test indicative of heart failure. Additionally, BNP can be used to differentiate between causes of dyspnea due to heart failure from other causes of dyspnea. If myocardial infarction is suspected, various [cardiac markers](#) may be used.

According to a [meta-analysis](#) comparing BNP and N-terminal pro-BNP (NTproBNP) in the diagnosis of heart failure, BNP is a better indicator for heart failure and left ventricular systolic dysfunction. In groups of symptomatic patients, a diagnostic [odds ratio](#) of 27 for BNP compares with a [sensitivity](#) of 85% and [specificity](#) of 84% in detecting heart failure.^[37]

Angiography [\[edit\]](#)

Heart failure may be the result of coronary artery disease, and its prognosis depends in part on the ability of the [coronary arteries](#) to supply blood to the [myocardium](#) (heart muscle). As a result, [coronary catheterization](#) may be used to identify possibilities for revascularisation through [percutaneous coronary intervention](#) or [bypass surgery](#).

Monitoring [\[edit\]](#)

Various measures are often used to assess the progress of patients being treated for heart failure. These include [fluid balance](#) (calculation of fluid intake and excretion), monitoring [body weight](#) (which in the shorter term reflects fluid shifts).^[38]

Classification [\[edit\]](#)

There are many different ways to categorize heart failure, including:

- the side of the heart involved (left heart failure versus right heart failure). Right heart failure compromises pulmonary flow to the lungs. Left heart failure compromises aortic flow to the body and brain. Mixed presentations are common; left heart failure often leads to right heart failure in the longer term.
- whether the abnormality is due to insufficient [contraction](#) ([systolic dysfunction](#)), or due to insufficient relaxation of the heart ([diastolic dysfunction](#)), or to both.
- whether the problem is primarily increased venous back pressure ([preload](#)), or failure to supply adequate arterial perfusion ([afterload](#)).
- whether the abnormality is due to low cardiac output with high [systemic vascular resistance](#) or high cardiac output with low vascular resistance (low-output heart failure vs. high-output heart failure).
- the degree of functional impairment conferred by the abnormality (as reflected in the [New York Heart Association Functional Classification](#)^[39])
- the degree of coexisting illness: i.e. heart failure/systemic hypertension, heart failure/pulmonary hypertension, heart failure/diabetes, heart failure/kidney failure, etc.

Functional classification generally relies on the New York Heart Association functional classification. The

classes (I-IV) are:

- Class I: no limitation is experienced in any activities; there are no symptoms from ordinary activities.
- Class II: slight, mild limitation of activity; the patient is comfortable at rest or with mild exertion.
- Class III: marked limitation of any activity; the patient is comfortable only at rest.
- Class IV: any physical activity brings on discomfort and symptoms occur at rest.

This score documents severity of symptoms, and can be used to assess response to treatment. While its use is widespread, the NYHA score is not very reproducible and does not reliably predict the walking distance or exercise tolerance on formal testing.^[40]

In its 2001 guidelines the [American College of Cardiology/American Heart Association](#) working group introduced four stages of heart failure:^[41]

- Stage A: Patients at high risk for developing HF in the future but no functional or structural heart disorder.
- Stage B: a structural heart disorder but no symptoms at any stage.
- Stage C: previous or current symptoms of heart failure in the context of an underlying structural heart problem, but managed with medical treatment.
- Stage D: advanced disease requiring hospital-based support, a heart transplant or [palliative care](#).

The ACC staging system is useful in that Stage A encompasses "pre-heart failure" – a stage where intervention with treatment can presumably prevent progression to overt symptoms. ACC Stage A does not have a corresponding NYHA class. ACC Stage B would correspond to NYHA Class I. ACC Stage C corresponds to NYHA Class II and III, while ACC Stage D overlaps with NYHA Class IV.

Algorithms [\[edit\]](#)

There are various [algorithms](#) for the diagnosis of heart failure. For example, the algorithm used by the [Framingham Heart Study](#) adds together criteria mainly from physical examination. In contrast, the more extensive algorithm by the [European Society of Cardiology](#) (ESC) weights the difference between supporting and opposing parameters from the [medical history](#), [physical examination](#), further medical tests as well as response to therapy.

Framingham criteria [\[edit\]](#)

By the Framingham criteria, diagnosis of congestive heart failure (heart failure with impaired pumping capability)^[17] requires the simultaneous presence of at least 2 of the following major criteria or 1 major criterion in conjunction with 2 of the following minor criteria. Major criteria include an [enlarged heart](#) on a [chest x-ray](#), an S3 gallop (a [third heart sound](#)), [acute pulmonary edema](#), [episodes of waking up from sleep gasping for air](#), [crackles](#) on lung [auscultation](#), [central venous pressure](#) of more than 16 cm H₂O at the right atrium, [jugular vein distension](#), positive [abdominojugular test](#), and [weight loss](#) of more than 4.5 kg in 5 days in response to treatment (sometimes^[42] classified as a minor criterion).^[43] Minor criteria include an [abnormally fast heart rate](#) of more than 120 beats per minute, [nocturnal cough](#), [difficulty breathing](#) with physical activity, [pleural effusion](#), a decrease in the [vital capacity](#) by one third from maximum recorded, [liver enlargement](#), and bilateral [ankle swelling](#).^[43]

Minor criteria are acceptable only if they can not be attributed to another medical condition such as [pulmonary hypertension](#), [chronic lung disease](#), [cirrhosis](#), [ascites](#), or the [nephrotic syndrome](#).^[43] The Framingham Heart Study criteria are 100% sensitive and 78% specific for identifying persons with definite congestive heart failure.^[43]

ESC algorithm [\[edit\]](#)

The [ESC](#) algorithm weights the following parameters in establishing the diagnosis of heart failure:^[44]

Diagnostic assessments supporting the presence of heart failure

Assessment	Diagnosis of heart failure	
	Supports if present	Opposes if normal or absent
Compatible symptoms	++	++
Compatible signs	++	+
Cardiac dysfunction on echocardiography	+++	+++
Response of symptoms or signs to therapy	+++	++
ECG		
Normal		++

Abnormal	++	+
Dysrhythmia	+++	+
Laboratory		
Elevated BNP/NT-proBNP	+++	+
Low/normal BNP/NT-proBNP	+	+++
Low blood sodium	+	+
Kidney dysfunction	+	+
Mild elevations of troponin	+	+
Chest X-ray		
Pulmonary congestion	+++	+
Reduced exercise capacity	+++	++
Abnormal pulmonary function tests	+	+
Abnormal hemodynamics at rest	+++	++
+ = some importance; ++ = intermediate importance; +++ = great importance.		

Differential diagnosis [\[edit\]](#)

There are several terms which are closely related to heart failure, and may be the cause of heart failure, but should not be confused with it. [Cardiac arrest](#) and [asystole](#) refer to situations in which there is *no* cardiac output at all. Without urgent treatment these result in sudden death. [Myocardial infarction](#) ("Heart attack") refers to heart muscle damage due to insufficient blood supply, usually as a result of a blocked [coronary artery](#). [Cardiomyopathy](#) refers specifically to problems within the heart muscle, and these problems can result in heart failure. Ischemic cardiomyopathy implies that the cause of muscle damage is [coronary artery disease](#). [Dilated cardiomyopathy](#) implies that the muscle damage has resulted in enlargement of the heart. [Hypertrophic cardiomyopathy](#) involves enlargement and *thickening* of the heart muscle.

Management [\[edit\]](#)

Main article: [Management of heart failure](#)

Treatment focuses on improving the symptoms and preventing the progression of the disease. Reversible causes of the heart failure also need to be addressed (e.g. [infection](#), [alcohol](#) ingestion, anemia, [thyrotoxicosis](#), [arrhythmia](#), hypertension). Treatments include lifestyle and pharmacological modalities, and occasionally various forms of device therapy and rarely cardiac transplantation.

Acute decompensation [\[edit\]](#)

Main article: [Acute decompensated heart failure](#)

In [acute decompensated heart failure](#) (ADHF), the immediate goal is to re-establish adequate perfusion and oxygen delivery to end organs. This entails ensuring that [airway](#), [breathing](#), and [circulation](#) are adequate. Immediate treatments usually involve some combination of vasodilators such as nitroglycerin, diuretics such as furosemide, and possibly [non invasive positive pressure ventilation](#) (NIPPV).

Chronic management [\[edit\]](#)

The goals of treatment for people with chronic heart failure are the prolongation of life, the prevention of acute decompensation and the reduction of symptoms, allowing for greater activity.

Heart failure can result from a variety of conditions. In considering therapeutic options, it is important to first exclude reversible causes, including [thyroid disease](#), [anemia](#), chronic [tachycardia](#), [alcohol abuse](#), [hypertension](#) and dysfunction of one or more [heart valves](#). Treatment of the underlying cause is usually the first approach in treating heart failure. However, in the majority of cases, either no primary cause is found or treatment of the primary cause does not restore normal heart function. In these cases, [behavioral](#), [medical](#) and [device](#) treatment strategies exist which can provide significant improvement in outcomes, including the relief of symptoms, exercise tolerance, and a decrease in the likelihood of [hospitalization](#) or death.

Lifestyle [\[edit\]](#)

Behavioral modification is a primary consideration in any chronic heart failure management program, with [dietary guidelines](#) regarding [fluid](#) and [salt](#) intake being of particular importance.^[45]

Exercise should be encouraged and tailored to suit individual capabilities. The inclusion of regular physical

conditioning as part of a cardiac rehabilitation program can significantly improve [quality of life](#) and reduce the risk of hospital admission for worsening symptoms however there is no evidence for a reduction in mortality rates as a result of exercise. Furthermore, it is not clear whether this evidence can be extended to people with heart failure with preserved ejection fraction (HFpEF) or to those whose exercise regimen takes place entirely at home.^[46]

Home visits and regular monitoring at heart failure clinics reduce the need for hospitalization and improve [life expectancy](#).^[47]

Medication [\[edit\]](#)

First-line therapy for people with heart failure due to reduced systolic function should include [angiotensin-converting enzyme \(ACE\) inhibitors](#) (ACE-I) or [angiotensin receptor blockers](#) (ARBs). Use of medicines from this class are associated with improved survival and quality of life in people with heart failure.^[48]

[Beta-adrenergic blocking agents](#) (beta blockers) also form part of the first line of treatment, adding to the improvement in symptoms and [mortality](#) provided by ACE-I/ARB.^[48] The mortality benefits of beta blockers in people with systolic dysfunction who also have [atrial fibrillation](#) (AF) is more limited than in those who do not have AF.^[49] If the ejection fraction is not diminished (HFpEF), the benefits of beta blockers is more modest; a decrease in mortality has been observed but reduction in hospital admission for uncontrolled symptoms has not been observed.^[50]

In people who are intolerant of ACE-I and ARBs or who have significant renal dysfunction, the use of combined [hydralazine](#) and a long-acting nitrate, such as [isosorbide dinitrate](#), are an effective alternative. This regimen has been shown to reduce mortality in people with moderate heart failure.^[51] It is especially beneficial in African-Americans (AA).^[51] In AAs who are symptomatic, hydralazine and isosorbide dinitrate (H+I) can be added to ACE-I or ARBs.

In people with markedly reduced ejection fraction, the use of an aldosterone antagonist, in addition to beta blockers and ACE-I, can improve symptoms and reduce mortality.^{[52][53]}

Second-line drugs for CHF do not confer a mortality benefit. [Digitalis](#) is one such drug. Its narrow therapeutic window, high degree of toxicity, and the failure of multiple trials to show a mortality benefit have reduced its role in clinical practice. It is now used in only a small number of people with refractory symptoms, who are in atrial fibrillation and/or who have chronic [low blood pressure](#).

Diuretics have been a mainstay of treatment for treatment of fluid accumulation, and include diuretics classes such as loop diuretics, [thiazide-like diuretic](#), and [potassium-sparing diuretic](#). Although widely used, evidence on their efficacy and safety is limited, with the exception of spironolactone antagonists.^{[52][54]} A recent Cochrane review found that in small studies, the use of diuretics appeared to have improved mortality in individuals with heart failure.^[55] However, the extent to which these results can be extrapolated to a general population is unclear due to the small number of participants in the cited studies.^[54]

[Anemia](#) is an independent factor in mortality in people with chronic heart failure. The treatment of anemia significantly improves quality of life for those with heart failure, often with a reduction in severity of the NYHA classification, and also improves mortality rates.^{[56][57]} The latest European guidelines (2012) recommend screening for iron-deficient anemia and treating with [parenteral iron](#) if anemia is found.^[58]

Minimally invasive therapies [\[edit\]](#)

In people with severe cardiomyopathy (left ventricular ejection fraction below 35%), or in those with recurrent VT or malignant arrhythmias, treatment with an [automatic implantable cardioverter defibrillator](#) (AICD) is indicated to reduce the risk of severe life-threatening arrhythmias. The AICD does not improve symptoms or reduce the incidence of malignant arrhythmias, but does reduce mortality from those arrhythmias, often in conjunction with antiarrhythmic medications. In people with left ventricular ejection (LVEF) below 35%, the incidence of [ventricular tachycardia](#) (VT) or [sudden cardiac death](#) is high enough to warrant AICD placement. Its use is therefore recommended in [AHA/ACC](#) guidelines.^[14]

[Cardiac contractility modulation](#) (CCM) is a [treatment](#) for people with moderate to severe [left ventricular systolic heart failure](#) ([NYHA class II–IV](#)) which enhances both the strength of ventricular [contraction](#) and the heart's pumping capacity. The CCM mechanism is based on stimulation of the cardiac muscle by [non-excitatory electrical signals](#) (NES), which are delivered by a [pacemaker](#)-like device. CCM is particularly suitable for the treatment of heart failure with normal [QRS complex](#) duration (120 ms or less) and has been demonstrated to improve the symptoms, quality of life and exercise tolerance.^{[15][59][60][61][62]} CCM is approved for use in Europe, but not currently in North America.^{[63][64]}

About one third of people with [LVEF](#) below 35% have markedly altered conduction to the ventricles, resulting in

dyssynchronous depolarization of the right and left ventricles. This is especially problematic in people with left bundle branch block (blockage of one of the two primary conducting fiber bundles that originates at the base of the heart and carries depolarizing impulses to the left ventricle). Using a special pacing algorithm, biventricular [cardiac resynchronization therapy](#) (CRT) can initiate a normal sequence of ventricular depolarization. In people with LVEF below 35% and prolonged QRS duration on ECG (LBBB or QRS of 150 ms or more) there is an improvement in symptoms and mortality when CRT is added to standard medical therapy.^[65] However, in the two thirds of people without prolonged QRS duration, CRT may actually be harmful.^{[14][15][66]}

Surgical therapies [\[edit\]](#)

People with the most severe heart failure may be candidates for [ventricular assist devices](#) (VAD). VADs have commonly been used as a bridge to heart transplantation, but have been used more recently as a destination treatment for advanced heart failure.^[67]

In select cases, [heart transplantation](#) can be considered. While this may resolve the problems associated with heart failure, the person must generally remain on an immunosuppressive regimen to prevent rejection, which has its own significant downsides.^[68] A major limitation of this treatment option is the scarcity of hearts available for transplantation.

Palliative care [\[edit\]](#)

People with CHF often have significant symptoms, such as shortness of breath and chest pain. Both palliative care and cardiology are trying to get palliative care involved earlier in the course of patients with heart failure, and some would argue^[who?] any patient with NYHA class III CHF should have a palliative care referral. Palliative care can not only provide symptom management, but also assist with advanced care planning, goals of care in the case of a significant decline, and making sure the patient has a medical [power of attorney](#) and discussed his or her wishes with this individual.^[69]

Without transplantation, heart failure may not be reversible and cardiac function typically deteriorates with time. The growing number of patients with Stage IV heart failure (intractable symptoms of fatigue, shortness of breath or chest pain at rest despite optimal medical therapy) should be considered for palliative care or hospice, according to American College of Cardiology/American Heart Association guidelines.^[69]

Prognosis [\[edit\]](#)

Prognosis in heart failure can be assessed in multiple ways including clinical prediction rules and cardiopulmonary exercise testing. Clinical prediction rules use a composite of clinical factors such as lab tests and blood pressure to estimate prognosis. Among several [clinical prediction rules](#) for prognosing acute heart failure, the 'EFFECT rule' slightly outperformed other rules in stratifying patients and identifying those at low risk of death during hospitalization or within 30 days.^[70] Easy methods for identifying low risk patients are:

- ADHERE Tree rule indicates that patients with [blood urea nitrogen](#) < 43 mg/dl and [systolic blood pressure](#) at least 115 mm Hg have less than 10% chance of inpatient death or complications.
- BWH rule indicates that patients with systolic blood pressure over 90 mm Hg, respiratory rate of 30 or less breaths per minute, serum sodium over 135 mmol/L, no new ST-T wave changes have less than 10% chance of inpatient death or complications.

A very important method for assessing prognosis in advanced heart failure patients is cardiopulmonary exercise testing (CPX testing). CPX testing is usually required prior to heart transplantation as an indicator of prognosis. Cardiopulmonary exercise testing involves measurement of exhaled oxygen and carbon dioxide during exercise. The peak oxygen consumption (VO2 max) is used as an indicator of prognosis. As a general rule, a VO2 max less than 12–14 cc/kg/min indicates a poor survival and suggests that the patient may be a candidate for a heart transplant. Patients with a VO2 max<10 cc/kg/min have clearly poorer prognosis. The most recent International Society for Heart and Lung Transplantation (ISHLT) guidelines^[71] also suggest two other parameters that can be used for evaluation of prognosis in advanced heart failure, the heart failure survival score and the use of a criterion of VE/VCO2 slope > 35 from the CPX test. The heart failure survival score is a score calculated using a combination of clinical predictors and the VO2 max from the cardiopulmonary exercise test.

Heart failure is associated with significantly reduced physical and mental health, resulting in a markedly decreased [quality of life](#).^{[72][73]} With the exception of heart failure caused by reversible conditions, the condition usually worsens with time. Although some people survive many years, progressive disease is associated with an overall annual mortality rate of 10%.^[74]

Epidemiology [\[edit\]](#)

Heart failure is associated with a high health expenditure, mostly because of the cost of hospitalizations; costs have been estimated to amount to 2% of the total budget of the [National Health Service](#) in the United Kingdom, and more than \$35 billion in the United States.^{[75][76]}

Heart failure is the leading cause of hospitalization in people older than 65.^[77] In developed countries, the mean age of patients with heart failure is 75 years old. In developing countries, two to three percent of the population have heart failure, but in those 70 to 80 years old, it occurs in 20–30 percent.

More than 20 million people have heart failure worldwide.^{[78][79]} The prevalence and incidence of heart failure are increasing, mostly because of increasing life span, but also because of increased prevalence of risk factors (hypertension, diabetes, dyslipidemia, and obesity) and improved survival rates from other types of cardiovascular disease (myocardial infarction, valvular disease, and arrhythmias).^{[79][80]}

In the United States, heart failure affects 5.8 million people, and each year 550,000 new cases are diagnosed.^[78] In 2011, congestive heart failure was the most common reason for hospitalization for adults aged 85 years and older, and the second most common for adults aged 65–84 years.^[81] It is estimated that one in five adults at age 40 will develop heart failure during their remaining lifetime and about half of people who develop heart failure die within 5 years of diagnosis.^[82] Heart failure is much higher in African Americans, Hispanics, Native Americans and recent immigrants from the eastern bloc countries like Russia. This high prevalence in these ethnic minority populations has been linked to high incidence of diabetes and hypertension. In many new immigrants to the U.S., the high prevalence of heart failure has largely been attributed to lack of [preventive health care](#) or substandard treatment.^[83] Nearly one out of every four patients (24.7%) hospitalized in the U.S. with congestive heart failure are readmitted within 30 days.^[84] Additionally, more than 50% of patients seek re-admission within 6 months after treatment and the average duration of hospital stay is 6 days.

In tropical countries, the most common cause of HF is [valvular heart disease](#) or some type of [cardiomyopathy](#). As underdeveloped countries have become more affluent, there has also been an increase in the incidence of [diabetes](#), [hypertension](#) and [obesity](#), which have in turn raised the incidence of heart failure.^[85]

Congestive heart failure is a leading cause of hospital readmissions in the U.S. In a study of 18 States, Medicare patients aged 65 and older were readmitted at a rate of 24.5 per 100 admissions in 2011. In the same year, Medicaid patients were readmitted at a rate of 30.4 per 100 admissions, and uninsured patients were readmitted at a rate of 16.8 per 100 admissions. These are the highest readmission rates for both patient categories. Notably, congestive heart failure was not among the top ten conditions with the most 30-day readmissions among the privately insured.^[86]

Sex ^[edit]

Men have a higher incidence of heart failure, but the overall prevalence rate is similar in both sexes, since women survive longer after the onset of heart failure.^[87] Women tend to be older when diagnosed with heart failure (after [menopause](#)), they are more likely than men to have diastolic dysfunction, and seem to experience a lower overall quality of life than men after diagnosis.^[87]

Economics ^[edit]

In 2011, non-hypertensive congestive heart failure was one of the ten most expensive conditions seen during inpatient hospitalizations in the U.S., with aggregate inpatient hospital costs of more than \$10.5 billion.^[88]

Research ^[edit]

There is low quality evidence that [stem cell therapy](#) may help.^[89] Although this evidence positively indicated benefit, the evidence was of lower quality than other evidence that does not indicate benefit.^[90]

A previous claim, which came from a 2012 article published by the British Journal *Heart*, stated that a low salt diet increased the risk of death in those with congestive heart failure. This claim has since been withdrawn. The paper was retracted by the journal in 2013 because two of the cited studies contained duplicate data that could not be verified, and the data has since been lost.^{[91][92][93]}

References ^[edit]

- [^] "heart failure" at *Dorland's Medical Dictionary*
- [^] "Heart failure" . *Health Information*. Mayo Clinic. 23 December 2009. DS00061.
- [^] "Definition of Heart failure" . *Medical Dictionary*. MedicineNet. 27 April 2011.
- [^] "Living Well With Chronic Heart Failure" (PDF). *Heart Foundation*. p. 18. Retrieved 25 May 2014.
- ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j "Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update". *National Clinical Guideline Centre*: 19–24. Aug 2010. PMID 22741186 .

6. ^{a b} McDonagh, Theresa A. (2011). *Oxford textbook of heart failure*. Oxford: Oxford University Press. p. 3. ISBN 9780199577729.
7. ^{a b c} McMurray JJ, Pfeffer MA (2005). "Heart failure". *Lancet* **365** (9474): 1877–89. doi:10.1016/S0140-6736(05)66621-4. PMID 15924986.
8. ^{a b} "Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update". *National Clinical Guideline Centre*: 38–70. Aug 2010. PMID 22741186.
9. ^a *Willard & Spackman's occupational therapy*. (12th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2014. p. 1124. ISBN 9781451110807.
10. ^{a b} Eyal Herzog (2012). *The Cardiac Care Unit Survival Guide*. Lippincott Williams & Wilkins. p. 98. ISBN 9781451177466.
11. ^{a b c d e f} "Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update". *National Clinical Guideline Centre*: 34–47. Aug 2010. PMID 22741186.
12. ^{a b c d} "Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update". *National Clinical Guideline Centre*: 71–153. Aug 2010. PMID 22741186.
13. ^{a b} Taylor, RS; Sagar, VA; Davies, EJ; Briscoe, S; Coats, AJ; Dalal, H; Lough, F; Rees, K; Singh, S (Apr 27, 2014). "Exercise-based rehabilitation for heart failure." *The Cochrane database of systematic reviews* **4**: CD003331. doi:10.1002/14651858.CD003331.pub4. PMID 24771460.
14. ^{a b c} Tracy, CM et al. (Oct 2, 2012). "2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. [corrected]." (PDF). *Circulation* **126** (14): 1784–1800. doi:10.1161/CIR.0b013e3182618569. PMID 22965336. Retrieved Apr 29, 2015.
15. ^{a b c} Kuck, K.-H. et al. (Jan 2014). "New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association" (PDF). *Europace* **16** (1): 109–128. doi:10.1093/europace/eut311. PMID 24265466. Retrieved Oct 13, 2014.
16. ^a Dickstein K, Cohen-Solal A, Filippatos G et al. (October 2008). "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)" . *Eur. Heart J.* **29** (19): 2388–442. doi:10.1093/eurheartj/ehn309. PMID 18799522.
17. ^{a b} "congestive heart failure" at *Dorland's Medical Dictionary*
18. ^a "Ejection Fraction Heart Failure Measurement" . American Heart Association. Feb 11, 2014. Retrieved 7 June 2014.
19. ^{a b} "Ejection Fraction" . *Heart Rhythm Society*. Retrieved 7 June 2014.
20. ^a Jessup M, Abraham WT, Casey DE et al. (April 2009). "2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation" . *Circulation* **119** (14): 1977–2016. doi:10.1161/CIRCULATIONAHA.109.192064. PMID 19324967.
21. ^{a b} "high-output heart failure" at *Dorland's Medical Dictionary*
22. ^a "Heart Failure: Signs and Symptoms" . UCSF Medical Center.
23. ^a Fonarow GC, Abraham WT, Albert NM et al. (April 2008). "Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes: Findings From OPTIMIZE-HF". *Arch. Intern. Med.* **168** (8): 847–854. doi:10.1001/archinte.168.8.847. PMID 18443260.
24. ^a Nieminen MS, Böhm M, Cowie MR et al. (February 2005). "Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology" . *Eur. Heart J.* **26** (4): 384–416. doi:10.1093/eurheartj/ehi044. PMID 15681577.
25. ^a Coxib and traditional NSAID Trialists' (CNT), Collaboration; Bhala, N; Emberson, J; Merhi, A; Abramson, S; Arber, N; Baron, JA; Bombardier, C; Cannon, C; Farkouh, ME; FitzGerald, GA; Goss, P; Halls, H; Hawk, E; Hawkey, C; Hennekens, C; Hochberg, M; Holland, LE; Kearney, PM; Laine, L; Lanus, A; Lance, P; Laupacis, A; Oates, J; Patrono, C; Schnitzer, TJ; Solomon, S; Tugwell, P; Wilson, K; Wittes, J; Baigent, C (Aug 31, 2013). "Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials." . *Lancet* **382** (9894): 769–79. doi:10.1016/S0140-6736(13)60900-9. PMC 3778977. PMID 23726390.
26. ^a Boron, Walter F.; Boulpaep, Emile L. (2005). *Medical Physiology: A Cellular and Molecular Approach* (Updated ed.). Saunders. p. 533. ISBN 0-7216-3256-4.
27. ^a Rang HP (2003). *Pharmacology*. Edinburgh: Churchill Livingstone. p. 127. ISBN 0-443-07145-4.
28. ^a *cardiac pathophysiology in heart failure* at *GPnotebook*
29. ^a Shigeyama J, Yasumura Y, Sakamoto A et al. (December 2005). "Increased gene expression of collagen Types I and III is inhibited by beta-receptor blockade in patients with dilated cardiomyopathy". *Eur. Heart J.* **26** (24): 2698–705. doi:10.1093/eurheartj/ehi492. PMID 16204268.
30. ^a Tsutsui H, Matsushima S, Kinugawa S et al. (May 2007). "Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart" . *Hypertens. Res.* **30** (5): 439–49. doi:10.1291/hyres.30.439. PMID 17587756.

31. [▲] Krug AW, Grossmann C, Schuster C et al. (October 2003). "Aldosterone stimulates epidermal growth factor receptor expression". *J. Biol. Chem.* **278** (44): 43060–6. doi:10.1074/jbc.M308134200. PMID 12939263.
32. [▲] *systemic pathophysiology in heart failure* at GPnotebook
33. [▲] Hunter JG, Boon NA, Davidson S, Colledge NR, Walker B (2006). *Davidson's principles & practice of medicine*. Elsevier/Churchill Livingstone. p. 544. ISBN 0-443-10057-8.
34. [▲] Dworzynski, K; Roberts, E; Ludman, A; Mant, J; Guideline Development, Group (8 October 2014). "Diagnosing and managing acute heart failure in adults: summary of NICE guidance.". *BMJ (Clinical research ed.)* **349**: g5695. doi:10.1136/bmj.g5695. PMID 25296764.
35. [▲] Al Deeb, M; Barbic, S; Featherstone, R; Dankoff, J; Barbic, D (August 2014). "Point-of-care ultrasonography for the diagnosis of acute cardiogenic pulmonary edema in patients presenting with acute dyspnea: a systematic review and meta-analysis.". *Academic emergency medicine : official journal of the Society for Academic Emergency Medicine* **21** (8): 843–52. doi:10.1111/acem.12435. PMID 25176151.
36. [▲] Loscalzo, Joseph; Fauci, Anthony S.; Braunwald, Eugene; Dennis L. Kasper; Hauser, Stephen L; Longo, Dan L. (2008). *Harrison's Principles of Internal Medicine* (17 ed.). McGraw-Hill Medical. p. 1447. ISBN 978-0-07-147693-5.
37. [▲] Ewald B, Ewald D, Thakkestian A, Attia J (2008). "Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction". *Intern Med J* **38** (2): 101–13. doi:10.1111/j.1445-5994.2007.01454.x. PMID 18290826.
38. [▲] Yu, Cheuk-Man; Wang, Li; Chau, Elaine; Chan, Raymond Hon-Wah; Kong, Shun-Ling; Tang, Man-Oi (1 August 2005). "Correlation With Fluid Status and Feasibility of Early Warning Preceding Hospitalization". *American Heart Association Journals* **112**: 841–848. doi:10.1161/CIRCULATIONAHA.104.492207. Retrieved 8 July 2014.
39. [▲] Criteria Committee, New York Heart Association (1964). *Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis* (6th ed.). Boston: Little, Brown. p. 114.
40. [▲] Raphael C, Briscoe C, Davies J et al. (2007). "Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure". *Heart* **93** (4): 476–82. doi:10.1136/hrt.2006.089656. PMC 1861501. PMID 17005715.
41. [▲] Hunt SA, Abraham WT, Chin MH et al. (2005). "ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult" (PDF). *Circulation* **112** (12): e154–235. doi:10.1161/CIRCULATIONAHA.105.167586. PMID 16160202.
42. [▲] Topic Review – Heart Failure By Osama Gusbi, MD. Albany Medical Review – January 2002
43. ^{▲ a b c d} "Framingham Criteria for Congestive Heart Failure". MedicalCRITERIA.com. 2005. In turn citing: Framingham study 1971
44. [▲] Dickstein K, Cohen-Solal A, Filippatos G et al. (October 2008). "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)". *Eur. Heart J.* **29** (19): 2388–442. doi:10.1093/eurheartj/ehn309. PMID 18799522. as PDF Also at doi:10.1016/j.ejheart.2008.08.005
45. [▲] Lifestyle changes for heart failure recommended by the American Heart Association.
46. [▲] Taylor, RS; Sagar, VA; Davies, EJ; Briscoe, S; Coats, AJ; Dalal, H; Lough, F; Rees, K; Singh, S (27 April 2014). "Exercise-based rehabilitation for heart failure". *The Cochrane database of systematic reviews* **4**: CD003331. doi:10.1002/14651858.CD003331.pub4. PMID 24771460.
47. [▲] Feltner, C; Jones, CD; Cené, CW; Zheng, ZJ; Sueta, CA; Coker-Schwimmer, EJ; Arvanitis, M; Lohr, KN; Middleton, JC; Jonas, DE (Jun 3, 2014). "Transitional care interventions to prevent readmissions for persons with heart failure: a systematic review and meta-analysis.". *Annals of internal medicine* **160** (11): 774–84. doi:10.7326/M14-0083. PMID 24862840.
48. ^{▲ a b} National Institute for Health and Clinical Excellence. *Clinical guideline 108: Chronic heart failure - Management of chronic heart failure in adults in primary and secondary care*. London, August 2010.
49. [▲] Kotecha, Dipak; Holmes, Jane; Krum, Henry; Altman, Douglas G; Manzano, Luis; Cleland, John G F; Lip, Gregory Y H; Coats, Andrew J S; Andersson, Bert; Kirchhof, Paulus; von Lueder, Thomas G; Wedel, Hans; Rosano, Giuseppe; Shibata, Marcelo C; Rigby, Alan; Flather, Marcus D (December 2014). "Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis". *The Lancet* **384** (9961): 2235–2243. doi:10.1016/S0140-6736(14)61373-8. PMID 25193873.
50. [▲] Liu, Feng; Chen, Yanmei; Feng, Xuguang; Teng, Zhonghua; Yuan, Ye; Bin, Jianping; Hosoda, Toru (5 March 2014). "Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis". *PLoS ONE* **9** (3): e90555. doi:10.1371/journal.pone.0090555. PMID 24599093.
51. ^{▲ a b} Chronic Heart Failure: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care: Partial Update [Internet]
52. ^{▲ a b} Pitt, B et al. (Sep 2, 2013). "The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.". *N Engl J Med* **341** (10): 709–717. PMID 10471456. Retrieved Apr 28, 2015.
53. [▲] Pitt, B et al. (Apr 3, 2013). "Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.". *N Engl J Med* **348** (14): 1309–1321. PMID 12668699. Retrieved Apr 28, 2015.
54. ^{▲ a b} von Lueder, TG; Atar, D; Krum, H (Oct 2013). "Diuretic use in heart failure and outcomes.". *Clinical pharmacology and therapeutics* **94** (4): 400–8. doi:10.1037/plt.2013.140. PMID 23952206.

- pharmacology and therapeutics 34 (4): 490–6. doi:10.1038/nrcl.2013.140. PMID 23692390.
55. ^ Faris, RF; Flather, M; Purcell, H; Poole-Wilson, PA; Coats, AJ (Feb 15, 2012). "Diuretics for heart failure.". *The Cochrane database of systematic reviews* 2: CD003838. doi:10.1002/14651858.CD003838.pub3. PMID 22336795.
56. ^ He SW, Wang LX (2009). "The impact of anemia on the prognosis of chronic heart failure: a meta-analysis and systemic review". *Congest Heart Fail* 15 (3): 123–30. doi:10.1111/j.1751-7133.2008.00030.x. PMID 19522961.
57. ^ Pereira-Moral J. Roberto, Núñez-Gil Ivan J. (19 January 2012). "Anaemia in heart failure: intravenous iron therapy". *E-journal of the ESC Council for Cardiology Practice* 10 (16).
58. ^ ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 European Heart Journal (2012) 33, 1787–1847 doi:10.1093/eurheartj/ehs104.
59. ^ Abraham, W.T.; S.A. Smith (Feb 2013). "Devices in the management of advanced, chronic heart failure" (PDF). *Nat Rev Cardiol* 10 (2): 98–110. doi:10.1038/nrcardio.2012.178. PMID 23229137. Retrieved Oct 10, 2014.
60. ^ Giallauria, F. et al. (Aug 2014). "Effects of cardiac contractility modulation by non-excitatory electrical stimulation on exercise capacity and quality of life: an individual patient's data meta-analysis of randomized controlled trials". *Int J Cardiol* 175 (2): 352–357. doi:10.1016/j.ijcard.2014.06.005. PMID 24975782.
61. ^ Borggrefe, M.; D. Burkhoff (Jul 2012). "Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure". *Eur J Heart Fail* 14 (7): 703–712. doi:10.1093/eurjhf/hfs078. PMID 22696514.
62. ^ Kuschyk, J. et al. (Jan 2015). "Efficacy and survival in patients with cardiac contractility modulation: Long-term single center experience in 81 patients". *Int J Cardiol* 20 (183C): 76–81. doi:10.1016/j.ijcard.2014.12.178. PMID 25662055. Retrieved Feb 19, 2015.
63. ^ Kuschyk, J. (2014). "Der Besondere Stellenwert der Kardialen Kontraktilitätsmodulation in der Devicetherapie". *Herzmedizin*. Retrieved Jun 6, 2014.
64. ^ clinicaltrials.gov Announcement of a study that will further investigate safety and efficacy of CCM devices.
65. ^ Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE et al. (2013). "2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". *Circulation* 128 (16): e240–e327. doi:10.1161/CIR.0b013e31829e8776. PMID 23741058.
66. ^ Ruschitzka, F et al. (Oct 10, 2013). "Cardiac-Resynchronization Therapy in Heart Failure with a Narrow QRS Complex". *N Engl J Med* 369 (15): 1395–1405. doi:10.1056/NEJMoa1306687. PMID 23998714. Retrieved Apr 29, 2015.
67. ^ Carrel, T; Englberger, L; Martinelli, MV; Takala, J; Boesch, C; Sigurdadottir, V; Gygax, E; Kadner, A; Mohacsi, P (Oct 18, 2012). "Continuous flow left ventricular assist devices: a valid option for heart failure patients.". *Swiss medical weekly* 142: w13701. doi:10.4414/smww.2012.13701. PMID 23135811.
68. ^ Lindenfeld, J et al. (Dec 14, 2004). "New Drugs and Technologies. Drug Therapy in the Heart Transplant Recipient. Part I: Cardiac Rejection and Immunosuppressive Drugs" (PDF). *Circulation* 110 (24): 3734–3740. PMID 15596559. Retrieved Apr 29, 2015.
69. ^ a b Adler, Eric D.; Goldfinger, Judith Z.; Kalman, Jill; Park, Michelle E.; Meier, Diane E. "Palliative Care in the Treatment of Advanced Heart Failure". *American Heart Association Journals* 120: 2597–2606. doi:10.1161/CIRCULATIONAHA.109.869123. Retrieved 8 July 2014.
70. ^ Auble TE, Hsieh M, McCausland JB, Yealy DM (2007). "Comparison of four clinical prediction rules for estimating risk in heart failure". *Annals of Emergency Medicine* 50 (2): 127–35, 135.e1–2. doi:10.1016/j.annemergmed.2007.02.017. PMID 17449141.
71. ^ Mehra MR, Kobashigawa J, Starling R et al. (September 2006). "Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates—2006". *J. Heart Lung Transplant*. 25 (9): 1024–42. doi:10.1016/j.healun.2006.06.008. PMID 16962464.
72. ^ Juenger J, Schellberg D, Kraemer S et al. (March 2002). "Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables". *Heart* 87 (3): 235–41. doi:10.1136/heart.87.3.235. PMC 1767036. PMID 11847161.
73. ^ Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK (December 2002). "Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population". *Eur. Heart J.* 23 (23): 1867–76. doi:10.1053/eurhj.2002.3255. PMID 12445536.
74. ^ Neubauer S (2007). "The failing heart – an engine out of fuel". *N Engl J Med* 356 (11): 1140–51. doi:10.1056/NEJMra063052. PMID 17360992.
75. ^ Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ (June 2002). "The current cost of heart failure to the National Health Service in the UK". *Eur. J. Heart Fail.* 4 (3): 361–71. doi:10.1016/S1388-9842(01)00198-2. PMID 12034163.
76. ^ Rosamond W, Flegal K, Furie K et al. (January 2008). "Heart disease and stroke statistics—2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee". *Circulation* 117 (4): e25–146. doi:10.1161/CIRCULATIONAHA.107.187998. PMID 18086926.
77. ^ Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI (2000). "Predictors of readmission among elderly survivors of admission with heart failure". *Am. Heart J.* 139 (1 Pt 1): 72–7. doi:10.1016/S0002-8703(00)90311-9. PMID 10618565.
78. ^ a b Bui, AL; Horwich, TB; Fonarow, GC (January 2011). "Epidemiology and risk profile of heart failure.". *Nature Reviews Cardiology* 8 (1): 30–41. doi:10.1038/nrcardio.2010.165. PMC 3033496. PMID 21060326.

79. ^{a b} Mann DL, Chakinala M (2012). *Harrison's principles of internal medicine: Chapter 234. Heart Failure and Cor Pulmonale*. (18th ed.). New York: McGraw-Hill. ISBN 978-0071748896.
80. ^a Goldman, Lee (2011). *Goldman's Cecil Medicine: Heart Failure (Ch 58, 59)* (24th ed.). Philadelphia: Elsevier Saunders. pp. 295–317. ISBN 1437727883.
81. ^a Pfuntner A., Wier L.M., Stocks C. Most Frequent Conditions in U.S. Hospitals, 2011. HCUP Statistical Brief #162. September 2013. Agency for Healthcare Research and Quality, Rockville, MD. [1]
82. ^a Go, AS; Mozaffarian, D; Roger, VL; Benjamin, EJ; Berry, JD; Borden, WB; Bravata, DM; Dai, S; Ford, ES; Fox, CS; Franco, S; Fullerton, HJ; Gillespie, C; Hailpern, SM; Heit, JA; Howard, VJ; Huffman, MD; Kissela, BM; Kittner, SJ; Lackland, DT; Lichtman, JH; Lisabeth, LD; Magid, D; Marcus, GM; Marelli, A; Matchar, DB; McGuire, DK; Mohler, ER; Moy, CS; Mussolino, ME; Nichol, G; Paynter, NP; Schreiner, PJ; Sorlie, PD; Stein, J; Turan, TN; Virani, SS; Wong, ND; Woo, D; Turner, MB; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (1 January 2013). "Heart disease and stroke statistics—2013 update: a report from the American Heart Association.". *Circulation* **127** (1): e6–e245. PMID 23239837.
83. ^a [Heart Failure Information](#), Retrieved on 2010-01-21.
84. ^a Elixhauser A, Steiner C. *Readmissions to U.S. Hospitals by Diagnosis, 2010*. HCUP Statistical Brief #153. Agency for Healthcare Research and Quality. April 2013. [2]
85. ^a [Melmed 2011](#), pp. 146
86. ^a Hines AL, Barrett ML, Jiang HJ, and Steiner CA. (April 2014). "Conditions With the Largest Number of Adult Hospital Readmissions by Payer, 2011." *HCUP Statistical Brief #172*. Rockville, MD: Agency for Healthcare Research and Quality.
87. ^{a b} Strömberg A, Mårtensson J. (Apr 2003). "Gender differences in patients with heart failure". *Eur. J. Cardiovasc. Nurs.* **2** (1): 7–18. doi:10.1016/S1474-5151(03)00002-1. PMID 14622644.
88. ^a Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011. HCUP Statistical Brief #160. Agency for Healthcare Research and Quality, Rockville, MD. August 2013. [3]
89. ^a Fisher, SA; Brunskill, SJ; Doree, C; Mathur, A; Taggart, DP; Martin-Rendon, E (Apr 29, 2014). "Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.". *The Cochrane database of systematic reviews* **4**: CD007888. doi:10.1002/14651858.CD007888.pub2. PMID 24777540.
90. ^a Nowbar, AN; Mielewicz, M; Karavassilis, M; Dehbi, HM; Shun-Shin, MJ; Jones, S; Howard, JP; Cole, GD; Francis, DP; DAMASCENE writing, group (Apr 28, 2014). "Discrepancies in autologous bone marrow stem cell trials and enhancement of ejection fraction (DAMASCENE): weighted regression and meta-analysis." *BMJ (Clinical research ed.)* **348**: g2688. doi:10.1136/bmj.g2688. PMC 4002982. PMID 24778175.
91. ^a Dinicolantonio, JJ; Pasquale, PD; Taylor, RS; Hackam, DG (Jan 24, 2013). "Low sodium versus normal sodium diets in systolic heart failure: systematic review and meta-analysis.". *Heart (British Cardiac Society)*. doi:10.1136/heartjnl-2012-302337. PMID 22914535.
92. ^a no author given (June 2013). "Retraction. Low sodium versus normal sodium diets in systolic heart failure: systematic review and meta-analysis. *Heart*. Published Online First: 21 August 2012 doi:10.1136/heartjnl-2012-302337" *Heart* **99** (11): 820. doi:10.1136/heartjnl-2011-301156.29ret. PMID 23640983. Retrieved 2013-09-29.
93. ^a amarcus41. "Heart pulls sodium meta-analysis over duplicated, and now missing, data" *Retraction Watch*. Retrieved 2013-09-29.

External links [\[edit\]](#)

- [Heart failure](#) [↗](#), American Heart Association – information and resources for treating and living with heart failure
- [Heart Failure Matters](#) [↗](#) – patient information website of the Heart Failure Association of the European Society of Cardiology
- [Heart failure in children](#) [↗](#) by Great Ormond Street Hospital, London, UK

 Wikimedia Commons has media related to [Heart failure](#).

v t e	Cardiovascular disease 100–152, 390–429	[show]
v t e	Organ failure	[show]
Authority control	NDL: 00571034 ↗	

Categories: [Aging-associated diseases](#) | [Heart diseases](#) | [Organ failure](#)